Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Evaluation of AL8326 in ≥2nd Line Small Cell Lung Cancer
2023-509067-24-00Phase 2Withdrawn
- Sponsor
- Advenchen Laboratories
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of AL8326 in small cell lung cancer (SCLC), sponsored by Advenchen Laboratories. Primary endpoints: Optimal biological dose (OBD) for AL8326 and Objective response rate (ORR). Planned start Jun 2024; status: withdrawn.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-509067-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509067-24-00.